Namita Thapar Emcure Pharmaceuticals:
Based on the red herring prospectus of Emcure Pharmaceuticals, where she partially sold her stock, Namita Thapar stands to make 293 times her initial investment.Thapar will get a 293-fold return at the top of the price range. Emcure Pharmaceuticals’ pricing range is Rs 960 to Rs 1008 per share.
With 6,339,800 shares in Emcure, Thapar owns 3.5 percent of the business. With her shares acquired at a weighted average cost of Rs 3.44, her total investment in the company now stands at Rs 2.18 crore. 1,268,600 Emcure shares will be sold by her through the offer-for-sale (OFS).
With a 41.85% stake in the company, Satish Ramanlal Mehta is another promoter who will take part in the OFS by giving up to 4,20,000 equity shares. He now owns 75,816,748 equity shares. Mehta will profit 52 times on the upper end of the pricing range compared to his initial investment.
Furthermore, shares in the OFS will be offloaded by Pushpa Rajnikant Mehta, Bhavana Satish Mehta, Kamini Sunil Mehta, Arunkumar Purshotamlal Khanna, Berjis Minoo Desai, and Sonali Sanjay Mehta.
The 1.14 crore equity shares that current shareholders, including the promoters, are offering for sale will be combined with a new equity issuance totaling Rs 800 crore to form the IPO.
Disclaimer: The views and investment tips expressed by experts on TheNewzShorts.com are their own and not those of the website or its management. TheNewzShorts.com advises users to check with certified experts before taking any investment decisions.
https://thenewzshorts.com/the-deadline-for-aadhaar/
